Newcastle based drug development company LightOx have secured further investment from London based NG Bio.
New Grounds are the latest to join our current funding round alongside several other investors – including Northstar Ventures, UK and Meneldor, Netherlands – supporting the company in the pre-clinical development of our lead compound LXD191 for the treatment of Oral Cancer lesions and also the further expansion of our light-activated technology platform.
LightOx CEO, Dr Sam Whitehouse says
“We are delighted that New Grounds have given their support for our work at LightOx. We have had a very busy 2021 and the investment from our partners have led to opening our own labs in Newcastle and the formulation of the lead compound, as well as development in new areas for the technology. We are continuing to expand our offering and look forward to sharing further developments and data in the coming months”
NG Bio Co-founder, Mohammad Khobreh says
“We are extremely excited about the opportunity to work with LightOx, and have been impressed by the team whose vision for LightOx is inspiring. We are looking forward to seeing this exciting technology improve patient outcomes. LightOx is another great example of world leading technologies developed by Universities across the UK.”
NG Bio is a London-based biotech focused on supporting scientific founders developing early-stage scientific discoveries into therapies that can change patient’s lives.